AdAlta Ltd (1AD) is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein.
AdAlta
Follow
Get notifications in MyBN when activity occurs.
Company Activity
NEW ROLE: Robert Peach, Non-Executive Director | 03 Jul 2024 | |
NEW ROLE: David Fuller, Non-Executive Director | 03 Nov 2020 | |
NEW ROLE: Liddy McCall, Non-Executive Director | 03 Nov 2020 | |
NEW ROLE: Paul MacLeman, Executive Chairman | 03 Nov 2020 | |
NEW ROLE: James Williams, Alternate Director | 03 Nov 2020 | |
NEW ROLE: Timothy Oldham, Managing Director, Chief Executive Officer | 03 Nov 2020 | |
NEW ROLE: Colin Boyan, Non-Executive Director | 03 Nov 2020 | |
NEW ROLE: Cameron Jones, Chief Financial Officer, Company Secretary | 03 Nov 2020 |